XERIJECT

Serial Number 90359515
606

Registration Progress

Application Filed
Dec 4, 2020
Under Examination
Aug 24, 2021
Approved for Publication
Jun 29, 2021
Published for Opposition
Jun 29, 2021
Registered

Trademark Image

XERIJECT

Basic Information

Serial Number
90359515
Filing Date
December 4, 2020
Published for Opposition
June 29, 2021
Abandonment Date
September 30, 2024
Drawing Code
4

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Sep 30, 2024
Classes
005

Rights Holder

Xeris Pharmaceuticals, Inc.

03
Address
180 N LaSalle Street, Suite 1810
Chicago, IL 60601

Ownership History

Xeris Pharmaceuticals, Inc.

Original Applicant
03
Chicago, IL

Xeris Pharmaceuticals, Inc.

Owner at Publication
03
Chicago, IL

Legal Representation

Attorney
Tracy-Gene G. Durkin

USPTO Deadlines

All Deadlines Cleared

All 2 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

42 events
Date Code Type Description Documents
Sep 30, 2024 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Loading...
Sep 30, 2024 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Feb 14, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Feb 13, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Feb 13, 2024 EX5G S SOU EXTENSION 5 GRANTED Loading...
Feb 13, 2024 EXT5 S SOU EXTENSION 5 FILED Loading...
Sep 13, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Sep 13, 2023 NOAC E CORRECTED NOA E-MAILED Loading...
Sep 12, 2023 DPCC D DIVISIONAL PROCESSING COMPLETE Loading...
Sep 12, 2023 EX4G S SOU EXTENSION 4 GRANTED Loading...
Aug 30, 2023 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Aug 24, 2023 ERTD I TEAS REQUEST TO DIVIDE RECEIVED Loading...
Aug 24, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Aug 24, 2023 DRRR I DIVISIONAL REQUEST RECEIVED Loading...
Aug 24, 2023 EXT4 S SOU EXTENSION 4 FILED Loading...
Feb 2, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jan 31, 2023 EX3G S SOU EXTENSION 3 GRANTED Loading...
Jan 31, 2023 EXT3 S SOU EXTENSION 3 FILED Loading...
Jan 31, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jun 23, 2022 ASCK I ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY Loading...
May 31, 2022 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
May 27, 2022 EX2G S SOU EXTENSION 2 GRANTED Loading...
May 27, 2022 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
May 27, 2022 EXT2 S SOU EXTENSION 2 FILED Loading...
May 19, 2022 ASCK I ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY Loading...
Dec 18, 2021 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Dec 16, 2021 EX1G S SOU EXTENSION 1 GRANTED Loading...
Dec 16, 2021 EXT1 S SOU EXTENSION 1 FILED Loading...
Dec 16, 2021 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Aug 24, 2021 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Jun 29, 2021 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jun 29, 2021 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jun 9, 2021 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
May 26, 2021 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
May 26, 2021 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
May 26, 2021 GNEA F EXAMINERS AMENDMENT E-MAILED Loading...
May 26, 2021 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
May 26, 2021 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
May 24, 2021 DOCK D ASSIGNED TO EXAMINER Loading...
May 12, 2021 ASCK I ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY Loading...
Feb 10, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Dec 8, 2020 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations for the treatment of diseases and conditions, namely, alimentary tract, metabolic, oncologic, autoimmune, and nervous system diseases and conditions; pharmaceutical preparations for the treatment of diseases and conditions, namely, anti-invectives to prevent or treat infections, vaccines, antineoplastic pharmaceutical preparations for the treatment of cancer, and immunomodulating pharmaceutical preparations for the treatment of immune system related diseases and disorders

Classification

International Classes
005